VKTX stock tumbles 29% today — Viking Therapeutics weight-loss trial results fuel massive investor sell-off and market jitters

Viking Therapeutics stock plunged after the release of its Phase 2 trial data, as safety questions overshadowed promising efficacy results.The company’s oral obesity drug candidate, VK2735, delivered up to 12.2% weight loss over just 13 weeks, a result that easily cleared trial goals and initially looked like a breakthrough.

But investor enthusiasm evaporated when details revealed a 28% discontinuation rate among patients—far higher than the placebo group.

That raised red flags about tolerability and long-term use, sending Viking shares tumbling nearly 40% in pre-market trading and sparking sharp debate among analysts over the drug’s commercial future.

A promising obesity drug meets market skepticism

Viking Therapeutics (NASDAQ: VKTX) delivered headline-grabbing results from its Phase 2 VENTURE trial this week. The company’s oral obesity drug candidate, VK2735, showed up to 12.2% average body weight reduction over 13 weeks, a figure that easily cleared both primary and secondary trial endpoints.

ALSO READ: XRP crashes below $3 today: a critical juncture — buy now or wait for the next surge? here’s what analysts say

On paper, that kind of efficacy would typically excite investors. Instead, shares collapsed in early trading—dropping more than 37% pre-market—as attention shifted from efficacy to tolerability.

Why Wall Street reacted so sharply

The sticking point was the 28% discontinuation rate among patients on VK2735, compared with 18% on placebo. That gap immediately raised concerns over long-term adherence and whether side effects could undermine commercial viability.

Investors, who had bid VKTX up more than 100% year-to-date, hit the sell button.

By mid-morning, the stock traded near $29.80, a steep fall from Monday’s close of $42.09. While some bargain hunters re-entered during intraday swings, sentiment clearly shifted.

Analysts split: efficacy strong, but tolerability divides opinion

Research houses wasted no time weighing in. Mizuho analysts compared Viking’s candidate to Eli Lilly’s oral GLP-1 therapy, highlighting that VK2735’s discontinuation rate was significantly higher—a potential red flag for prescribers.

On the other hand, JPMorgan’s Hardik Parikh struck a more balanced tone. He emphasized that at higher doses, patients lost 7.5–11% more weight than placebo, arguing that side effects appeared “manageable” and not disqualifying.

That divide between analyst camps underscores the central tension: does efficacy outweigh tolerability, or will safety worries cap enthusiasm until larger trials provide clarity?

Technicals add another layer of complexity

Just days before the data release, VKTX had been flashing strength. Its Relative Strength (RS) rating climbed from 61 to 82 in two sessions, placing it among the top-performing biotech names.

However, the stock had already run far past its earlier $3.50 breakout level, leaving little cushion for bad news. For traders, that meant a sharp pullback was almost inevitable once sentiment turned.

What this means for investors now

For retail and institutional investors alike, the message is clear: volatility isn’t going away. VKTX will likely trade in wide ranges as the market digests whether discontinuation rates can be reduced in Phase 3 trials or if formulation adjustments are needed.

• If you’re a long-term believer in GLP-1 innovation: VK2735’s efficacy profile is hard to ignore. Future trial designs may incorporate patient-selection strategies or titration protocols that improve tolerability.
  
  
• If you’re trading short-term momentum: VKTX is extended beyond classic buy points and is now vulnerable to deeper pullbacks. A retracement toward moving averages or the formation of a “three-weeks tight” pattern could offer cleaner entries.
  
  
• If you’re cautious: wait for updated Phase 3 trial timelines, safety disclosures, or regulatory commentary before committing capital.
  
  

Broader context: the GLP-1 arms race

The weight-loss drug market, led by Novo Nordisk’s Wegovy and Eli Lilly’s Zepbound, is one of the most lucrative races in pharma. Viking’s data puts it on the map as a legitimate contender, but execution will matter more than early efficacy headlines. Competitors have already set a high bar on both safety and commercial rollout, meaning any hint of tolerability weakness is magnified.

FAQs:

Q1: Why did Viking Therapeutics stock drop after its Phase 2 trial results?
Because investors worried about the high 28% discontinuation rate despite strong weight-loss efficacy.

Q2: Is Viking Therapeutics still a strong contender in the obesity drug market?
Yes, its efficacy is strong, but tolerability concerns must be addressed in Phase 3 trials.